Provectus Biopharmaceuticals Price Prediction

PVCTDelisted Stock  USD 0.11  0.00  0.00%   
At this time, The relative strength index (RSI) of Provectus Biopharmaceutica's share price is at 51 indicating that the otc stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling Provectus Biopharmaceutica, making its price go up or down.

Oversold Vs Overbought

51

 
Oversold
 
Overbought
Provectus Biopharmaceutica stock price prediction is an act of determining the future value of Provectus Biopharmaceutica shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Provectus Biopharmaceutica's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Provectus Biopharmaceutica and does not consider all of the tangible or intangible factors available from Provectus Biopharmaceutica's fundamental data. We analyze noise-free headlines and recent hype associated with Provectus Biopharmaceuticals, which may create opportunities for some arbitrage if properly timed.
Using Provectus Biopharmaceutica hype-based prediction, you can estimate the value of Provectus Biopharmaceuticals from the perspective of Provectus Biopharmaceutica response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Provectus Biopharmaceutica. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Provectus Biopharmaceutica to buy its otc stock at a price that has no basis in reality. In that case, they are not buying Provectus because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell otc stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Provectus Biopharmaceutica after-hype prediction price

    
  USD 0.11  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as otc price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Provectus Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.100.10.12
Details
Naive
Forecast
LowNextHigh
0.090.090.09
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.110.110.11
Details

Provectus Biopharmaceutica After-Hype Price Prediction Density Analysis

As far as predicting the price of Provectus Biopharmaceutica at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Provectus Biopharmaceutica or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of OTC Stock prices, such as prices of Provectus Biopharmaceutica, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Provectus Biopharmaceutica Estimiated After-Hype Price Volatility

In the context of predicting Provectus Biopharmaceutica's otc stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Provectus Biopharmaceutica's historical news coverage. Provectus Biopharmaceutica's after-hype downside and upside margins for the prediction period are 0.11 and 0.11, respectively. We have considered Provectus Biopharmaceutica's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0.11
0.11
After-hype Price
0.11
Upside
Provectus Biopharmaceutica is very steady at this time. Analysis and calculation of next after-hype price of Provectus Biopharmaceutica is based on 3 months time horizon.

Provectus Biopharmaceutica OTC Stock Price Prediction Analysis

Have you ever been surprised when a price of a OTC Stock such as Provectus Biopharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Provectus Biopharmaceutica backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the OTC price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Provectus Biopharmaceutica, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
 0.00  
0.00
 0.00  
 0.00  
0 Events / Month
12 Events / Month
Within a week
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.11
0.11
0.00 
0.00  
Notes

Provectus Biopharmaceutica Hype Timeline

Provectus Biopharmaceutica is at this time traded for 0.11. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Provectus is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at 0.0%. %. The volatility of related hype on Provectus Biopharmaceutica is about 0.0%, with the expected price after the next announcement by competition of 0.11. The company recorded a loss per share of 0.01. Provectus Biopharmaceutica had not issued any dividends in recent years. The entity had 1:300 split on the 11th of April 2002. Given the investment horizon of 90 days the next forecasted press release will be within a week.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Provectus Biopharmaceutica Related Hype Analysis

Having access to credible news sources related to Provectus Biopharmaceutica's direct competition is more important than ever and may enhance your ability to predict Provectus Biopharmaceutica's future price movements. Getting to know how Provectus Biopharmaceutica's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Provectus Biopharmaceutica may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
AVTEAerovate Therapeutics(0.33)4 per month 2.02  0.11  5.58 (3.86) 19.11 
CLDXCelldex Therapeutics(0.32)10 per month 0.00 (0.20) 5.53 (6.76) 17.16 
KNSAKiniksa Pharmaceuticals 0.22 9 per month 0.00 (0.12) 3.48 (3.98) 20.00 
CERECerevel Therapeutics Holdings 0.20 9 per month 0.94  0.04  1.91 (1.59) 6.40 
CRNXCrinetics Pharmaceuticals 0.12 9 per month 3.21 (0) 2.74 (5.14) 16.75 
IKNAIkena Oncology(0.01)2 per month 0.00 (0.12) 1.80 (2.35) 8.46 
XLOXilio Development(0.05)8 per month 5.29  0.12  12.50 (7.84) 57.76 
TARAProtara Therapeutics 0.07 8 per month 3.77  0.18  13.00 (6.48) 78.24 
SRRKScholar Rock Holding(2.28)8 per month 3.21  0.13  10.34 (6.99) 375.97 
ACXPAcurx Pharmaceuticals LLC(0.07)9 per month 0.00 (0.20) 8.70 (15.38) 34.95 
NGENFNervGen Pharma Corp 0.00 0 per month 4.97  0.03  8.90 (6.50) 33.14 
NBSENeuBase Therapeutics(0.18)1 per month 0.00 (0.17) 8.42 (11.84) 39.09 
CYCCCyclacel Pharmaceuticals(0.05)6 per month 0.00 (0.17) 12.87 (15.66) 48.10 
AXLAAxcella Health 0.01 1 per month 0.00 (0.17) 7.69 (9.68) 39.29 
IPSCCentury Therapeutics 0.07 8 per month 0.00 (0.10) 7.44 (7.74) 31.00 
KZRKezar Life Sciences 0.26 10 per month 2.67  0.04  4.93 (4.39) 51.13 
MLYSMineralys Therapeutics, Common 0.02 11 per month 3.61  0.02  7.51 (5.79) 20.98 
NKTXNkarta Inc(0.20)8 per month 0.00 (0.24) 6.50 (8.52) 25.45 
NGMNGM Biopharmaceuticals 0.00 0 per month 0.00 (0.13) 6.16 (8.80) 24.21 

Provectus Biopharmaceutica Additional Predictive Modules

Most predictive techniques to examine Provectus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Provectus using various technical indicators. When you analyze Provectus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Provectus Biopharmaceutica Predictive Indicators

The successful prediction of Provectus Biopharmaceutica stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Provectus Biopharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Provectus Biopharmaceutica based on analysis of Provectus Biopharmaceutica hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Provectus Biopharmaceutica's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Provectus Biopharmaceutica's related companies.

Story Coverage note for Provectus Biopharmaceutica

The number of cover stories for Provectus Biopharmaceutica depends on current market conditions and Provectus Biopharmaceutica's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Provectus Biopharmaceutica is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Provectus Biopharmaceutica's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Other Macroaxis Stories

Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios

Provectus Biopharmaceutica Short Properties

Provectus Biopharmaceutica's future price predictability will typically decrease when Provectus Biopharmaceutica's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Provectus Biopharmaceuticals often depends not only on the future outlook of the potential Provectus Biopharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Provectus Biopharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding419.4 M
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Consideration for investing in Provectus OTC Stock

If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities